NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) — Rezolute , Inc. (Nasdaq: NASDAQ:) (Rezolute or the Firm), a late-stage biopharmaceutical firm dedicated to creating novel, transformative therapies for critical uncommon ailments, at the moment introduced the pricing of its beforehand introduced underwritten public providing of an combination of 11,250,000 shares of its frequent inventory at an providing worth of $4.00 per share, and, to sure traders in lieu of frequent inventory, pre-funded warrants to buy as much as 3,750,000 shares of frequent inventory at an providing worth of $3.999 per pre-funded warrant, which represents the per share providing worth for the frequent inventory much less the $0.001 per share train worth for every pre-funded warrant. Gross proceeds from the underwritten public providing earlier than deducting underwriting reductions and commissions and different providing bills are anticipated to be roughly $60 million.
All shares of frequent inventory and pre-funded warrants to be bought within the providing shall be provided by Rezolute. The closing of the providing is predicted to happen on or about June 17, 2024, topic to the satisfaction of customary closing circumstances.
Jefferies and Cantor are performing because the joint book-running managers for the providing. BTIG, Craig-Hallum, H.C. Wainwright & Co., Jones and Maxim Group LLC are performing as co-managers for the providing.
A shelf registration assertion on Kind S-3 (File No. 333-275562) referring to the securities to be provided within the public providing was filed with the Securities and Trade Fee (the SEC) and was declared efficient on November 29, 2023. The general public providing shall be made solely by way of a prospectus complement and accompanying prospectus that type part of the registration assertion. A preliminary prospectus has been filed with the SEC and could also be obtained on the SEC’s web site at www.sec.gov. A last prospectus complement and the accompanying prospectus referring to and describing the phrases of the underwritten public providing shall be filed with the SEC and, when out there, could also be obtained on the SEC’s web site at www.sec.gov. Copies of the ultimate prospectus complement and accompanying prospectus referring to the general public providing, when out there, could also be obtained by contacting: Jefferies LLC, Consideration: Fairness Syndicate Prospectus Division, 520 Madison Avenue, New York, New York 10022, by phone at 877-821-7388, or by e-mail at prospectus_department@jefferies.com or Cantor Fitzgerald & Co., Consideration: Capital Markets, 110 East 59th Road, sixth Flooring, New York, New York 10022, or by e-mail at prospectus@cantor.com
This press launch doesn’t represent a proposal to promote, or a solicitation of a proposal to purchase these securities, nor shall there be any sale of, these securities in any state or jurisdiction wherein such provide, solicitation or sale can be illegal previous to registration or qualification beneath the securities legal guidelines of any such state or jurisdiction.
Rezolute, Inc.
Rezolute is a late-stage uncommon illness firm centered on considerably bettering outcomes for people with hypoglycemia brought on by hyperinsulinism (HI). The Firm’s antibody remedy, RZ358, is designed to deal with all types of HI and has proven substantial profit in medical trials and real-world use for the therapy of congenital hyperinsulinism and tumor hyperinsulinism.
Ahead-Wanting Statements
Any statements on this press launch in regards to the Firm’s future expectations, plans and prospects, together with statements concerning the general public providing, represent forward-looking statements for functions of the protected harbor provisions beneath the Non-public Securities Litigation Reform Act of 1995. Ahead-looking statements embrace any statements in regards to the Firm’s technique, future operations and future expectations and plans and prospects for the Firm, and every other statements containing the phrases anticipate, consider, estimate, count on, intend, objective, might, would possibly, plan, predict, mission, goal, potential, will, would, might, ought to, proceed, and related expressions. Such forward-looking statements contain substantial dangers and uncertainties that might trigger the Firm’s improvement applications, future outcomes, efficiency or achievements to vary considerably from these expressed or implied by the forward-looking statements. Such dangers and uncertainties embrace, amongst others, these associated to market and different monetary circumstances, the potential completion of the general public providing, satisfaction of customary closing circumstances associated to the general public providing and different components mentioned within the Threat Elements part contained within the preliminary prospectus complement and the studies that the Firm information with the SEC. Any forward-looking statements characterize the Firm’s views solely as of the date of this press launch. The Firm anticipates that subsequent occasions and developments will trigger its views to vary. Whereas the Firm might elect to replace these forward-looking statements sooner or later sooner or later, the Firm particularly disclaims any obligation to take action besides as required by legislation.
Contacts:
Rezolute, Inc.
Christen Baglaneas
cbaglaneas@rezolutebio.com
508-272-6717
LHA Investor Relations
Tirth T. Patel
tpatel@lhai.com
212-201-6614
